{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:10:33Z","timestamp":1792098633362,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.cllc.2016.04.004","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T16:13:25Z","timestamp":1462464805000},"page":"523-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-7528","authenticated-orcid":false,"given":"Kathleen","family":"Kerrigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Shoben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Otterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2016.04.004_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488706775246157","article-title":"Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC)","volume":"1","author":"Metro","year":"2006","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.cllc.2016.04.004_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/his.12379","article-title":"ROS1 expression and translocations in non-small-cell lung cancer: clinicopathologic analysis of 1478 cases","volume":"65","author":"Warth","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.cllc.2016.04.004_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.cllc.2013.04.006","article-title":"Crizotinib in the treatment of non-small-cell lung cancer","volume":"14","author":"Rothschild","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2016.04.004_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cllc.2016.04.004_bib5","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2016.04.004_bib6","first-page":"S579","article-title":"Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer","volume":"5","author":"Saves","year":"2013","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.cllc.2016.04.004_bib7","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1007\/s00134-009-1625-y","article-title":"Six month prognosis of patients with lung cancer admitted to the intensive care unit","volume":"35","author":"Roques","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cllc.2016.04.004_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1378\/chest.130.3.719","article-title":"Outcome and code status of lung cancer patients admitted to the medical ICU","volume":"130","author":"Reichner","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2016.04.004_bib9","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.lungcan.2012.05.103","article-title":"Outcomes of elderly patients with stage IIIB-IV non-small cell lung cancer admitted to the intensive care unit","volume":"77","author":"Bonomi","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2016.04.004_bib10","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1001\/jama.1986.03380240058028","article-title":"Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure","volume":"256","author":"Ewer","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2016.04.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-014-0847-1","article-title":"Who should be admitted to the intensive care unit? The outcome of intensive care unit admission in stage IIIB-IV lung cancer patients","volume":"31","author":"Kim","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.cllc.2016.04.004_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.lungcan.2014.07.010","article-title":"Successful empirical erlotinib treatment of a mechanically ventilated patient newly diangosed with metastatic lung adenocarcinoma","volume":"86","author":"Bosch-Barrera","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2016.04.004_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/JTO.0b013e3182746772","article-title":"Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-smell-cell lung cancer","volume":"8","author":"Ahn","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2016.04.004_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00134-005-2836-5","article-title":"Outcome in severely ill patients with hematologic malignancies who received intravenous chemotherapy in the intensive care unit","volume":"32","author":"Benoit","year":"2006","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cllc.2016.04.004_bib15","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non\u2013small- cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy","volume":"27","author":"Inoue","year":"2009","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041630064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573041630064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:05:52Z","timestamp":1761505552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573041630064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S152573041630064X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2016.04.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2016.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}